Stockscreener 앱 받기
84.83
0.54%
-0.46
전일 마감가:
$85.29
열려 있는:
$85.92
하루 거래량:
516.28K
Relative Volume:
1.17
시가총액:
$1.91B
수익:
$747.40M
순이익/손실:
$-12.60M
주가수익비율:
-110.36
EPS:
-0.7687
순현금흐름:
$105.18M
1주 성능:
+11.21%
1개월 성능:
+4.60%
6개월 성능:
+27.37%
1년 성능:
+47.53%
1일 변동 폭
$84.39
$87.07
1주일 범위
$79.35
$87.07
52주 변동 폭
$54.10
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(218) 634-3500
주소
210 MAIN STREET WEST, BAUDETTE, MN
ANIP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
84.83 | 1.92B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Guggenheim Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP) - The Globe and Mail
SG Americas Securities LLC Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Is Up 7.0% After Raising 2026 Revenue Outlook and Expanding Rare Disease Team - Yahoo Finance
Insider Sell Alert: Meredith Cook Sells Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals’ Cook sells $42,165 in stock By Investing.com - Investing.com Australia
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of Stock - MarketBeat
Ani Pharmaceuticals’ Cook sells $42,165 in stock - Investing.com
ANI Pharmaceuticals Targets $1B+ 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Stock Dips on Profit-Taking After 2026 GuidanceNews and Statistics - IndexBox
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - Finviz
Daily Breeze: Local News, Sports, Things to DoANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why - FinancialContent
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance (NASDAQ:ANIP) - Seeking Alpha
Stocks making big moves yesterday: OneMain, Nextpower, ANI Pharmaceuticals, Akamai Technologies, and Lemonade - The Globe and Mail
Growth Review: Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Performance Recap & Stepwise Trade Signal Implementation - Bộ Nội Vụ
Fund Flows: Why ANI Pharmaceuticals Inc stock remains undervaluedEarnings Risk Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
ANI Pharmaceuticals, Inc. (ANIP) Investor Outlook: Exploring a 29.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Decker Retirement Planning Inc. Boosts Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals expects over $1 billion in 2026 revenue By Investing.com - Investing.com Nigeria
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today - Finviz
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap UpTime to Buy? - MarketBeat
Ani Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2025 Earnings Guidance - MarketBeat
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities - The Manila Times
ANI Pharma is building a 90-person rare disease team for gout flares in 2026 - Stock Titan
ANI Pharmaceuticals (ANIP) Valuation Check After Robust 2025 Results And Raised Guidance - Sahm
How ANI Pharmaceuticals Inc. stock performs in weak economyWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - Улправда
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 6.3%Time to Sell? - MarketBeat
Momentum Shift: How ANI Pharmaceuticals Inc. stock performs in weak economyTrade Entry Summary & High Return Trade Guides - Улправда
How ANI Pharmaceuticals Inc. (BSFA) stock trades pre earningsPortfolio Performance Report & Fast Momentum Entry Tips - Улправда
Do Strong 2025 Rare Disease Results Reshape the Bull Case for ANI Pharmaceuticals (ANIP)? - Sahm
How ANI Pharmaceuticals Inc. stock reacts to global recession fears2025 Growth vs Value & Reliable Breakout Stock Forecasts - ulpravda.ru
Is ANI Pharmaceuticals Inc. (BSFA) stock a defensive play amid uncertainty2025 EndofYear Setup & Expert Verified Stock Movement Alerts - ulpravda.ru
What earnings margins imply for ANI Pharmaceuticals Inc. (BSFA) stockJuly 2025 Spike Watch & Consistent Return Investment Signals - ulpravda.ru
ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to "Hold" Rating by Zacks Research - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Nasdaq Today Specialty Pharma Focus - Kalkine Media
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Is ANI Pharmaceuticals (ANIP) Price Justified After Updated 2025 Revenue Guidance? - Yahoo Finance
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? - Your Wyoming Link
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis: A Healthcare Gem with 38.89% Upside Potential - DirectorsTalk Interviews
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead - The Globe and Mail
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
2025’s best-performing Minnesota public company stock is a biopharmaceutical firm with no revenue - Star Tribune
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Why You Should Add Encompass Health to Your Portfolio Now - Finviz
Revenue per share of ANI Pharmaceuticals, Inc. – MUN:BSFA - TradingView — Track All Markets
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Globe and Mail
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
1.45%
자본화:
|
볼륨(24시간):